Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 237-260

  Carlsson, A ^a   Waters, N ^a   Holm Waters, S ^a   Tedroff, J ^a   Nilsson, M ^a   Carlsson, M L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Dopamine; Movement disorders; Noradrenaline; Serotonin; Stabilization

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DIZOCILPINE; GLUTAMIC ACID; HALOPERIDOL; LEVODOPA; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RISPERIDONE;

DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; SCHIZOPHRENIA;

EID: 0035028512     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.237     Document Type: Review

References (48)

1. New morphological and neuropathological findings in schizophrenia: A neurodevelopmental perspective
2. The dopamine theory revisited
3. Striatal D2-dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography
4. Presynaptic dopaminergic function in the striatum of schizophrenic patients
5. Increased synthesis of dopamine in prefrontal cortex and striatum in drug-naive schizophrenic patients studied by use of C11-labelled I-DOPA and positron emission tomography (PET)
6. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
7. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
8. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
9. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia
10. (+)-UH 232 and (+)-UH 242: Novel stereoselective DA receptor antagonists with preferential action on autoreceptors
11. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships
12. On the quantitative structure-activity relationships of meta-substituted (S)-phenylpiperidines, a class of preferential dopamine D2 autoreceptor ligands. Modeling of dopamine synthesis and release in vivo by means of partial least squares regression
13. (-)-OSU6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease
14. Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease
15. (-)-OSU6162 induces a rapid onset of antipsychotic effect after a single dose. A double-blind study. Presented at Meet. Scand. Soc. Psychopharmacol., 41st
16. Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: A positron emission tomography study on patients and healthy volunteers
17. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
18. Schizophrenia and glutamate
19. Modulation of N-methylaspartate receptor channel complexes
20. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats
21. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs
22. Concurrent locomotor stimulation and decrease in dopamine in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755
23. Systemic PCP treatment elevates brain extracellular 5-HT: A microdialysis study in awake rats
24. The role of 5-HT2A receptors in antipsychotic activity
25. Rodent data and general hypothesis: Antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone
26. Evidence for biochemical heterogeneity in schizophrenia: A multivariate study of monoaminergic indices in human post-mortem brain tissue
27. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
28. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain
29. Co-release of noradrenaline and dopamine from noradrenergic neurons in the prefrontal cortex
30. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
31. Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation
32. Interactions between glutamatergic and monoaminergic systems within the basal ganglia: Implications for schizophrenia and Parkinson's disease
33. Interfering with glutamatergic neurotransmission by means of MK-801 administration discloses the locomotor stimulatory potential of other transmitter systems in rats and mice
34. The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse: Implications for psychosis
35. Emerging principles of altered neural circuitry in schizophrenia
36. The current status of the dopamine hypothesis of schizophrenia
37. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing
38. Hypothesis: Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways?
39. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice
40. On the roles of D-1 vs D-2 receptors for the hyperactivity response elicited by MK-801
41. Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications
42. D-Serine added to antipsychotics for the treatment of schizophrenia
43. Network interactions in schizophrenia: Therapeutic implications
44. IP-SPs in pyramidal cells in piriform cortex evoked by monoamine excitation of interneurons demonstrate a convergence of inputs
45. Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex
46. Muscimol: GABA agonist therapy in schizophrenia